Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elgene Lim

Showing results (101-110 of 130) with videos related to

Pageof 13
Sort By:
Nature Medicine|August 4, 2009
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersElgene Lim, François Vaillant, Di Wu, et al.
Acta Cytologica|May 22, 2019
The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy CytopathologyAndrew S Field, Wendy A Raymond, Mary Rickard, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.
Cancer Research|October 2, 2024
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast CancerCarolina Gemma, Chun-Fui Lai, Anup K Singh, et al.
Nature|March 28, 2014
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathwayXi Chen, Dimitrios Iliopoulos, Qing Zhang, et al.
Breast Cancer Research : BCR|March 23, 2019
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSean P Kennedy, Jeremy Z R Han, Neil Portman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast CancerKomal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Breast Cancer Research : BCR|August 4, 2021
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived modelsNicole J Chew, Terry C C Lim Kam Sian, Elizabeth V Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2025
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast CancersMadeline Gough, Kayden K X Kwah, Tashbib Khan, et al.
Nature Medicine|March 13, 2018
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signalingPernilla Roswall, Matteo Bocci, Michael Bartoschek, et al.
Pageof 13

Showing results (101-110 of 130) with videos related to

Sort By:
Pageof 13
Nature Medicine|August 4, 2009
Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriersElgene Lim, François Vaillant, Di Wu, et al.
Acta Cytologica|May 22, 2019
The International Academy of Cytology Yokohama System for Reporting Breast Fine-Needle Aspiration Biopsy CytopathologyAndrew S Field, Wendy A Raymond, Mary Rickard, et al.
Journal of Experimental & Clinical Cancer Research : CR|August 18, 2025
JNK pathway suppression mediates insensitivity to combination endocrine therapy and CDK4/6 inhibition in ER+ breast cancerSarah Alexandrou, Christine S Lee, Kristine J Fernandez, et al.
Cancer Research|October 2, 2024
Induction of the TEAD Coactivator VGLL1 by Estrogen Receptor-Targeted Therapy Drives Resistance in Breast CancerCarolina Gemma, Chun-Fui Lai, Anup K Singh, et al.
Nature|March 28, 2014
XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathwayXi Chen, Dimitrios Iliopoulos, Qing Zhang, et al.
Breast Cancer Research : BCR|March 23, 2019
Targeting promiscuous heterodimerization overcomes innate resistance to ERBB2 dimerization inhibitors in breast cancerSean P Kennedy, Jeremy Z R Han, Neil Portman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2023
Phase Ia/b Study of Giredestrant ± Palbociclib and ± Luteinizing Hormone-Releasing Hormone Agonists in Estrogen Receptor-Positive, HER2-Negative, Locally Advanced/Metastatic Breast CancerKomal L Jhaveri, Meritxell Bellet, Nicholas C Turner, et al.
Breast Cancer Research : BCR|August 4, 2021
Evaluation of FGFR targeting in breast cancer through interrogation of patient-derived modelsNicole J Chew, Terry C C Lim Kam Sian, Elizabeth V Nguyen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2025
Receptor CDCP1 Is a Potential Target for Personalized Imaging and Treatment of Poor Outcome HER2+, Triple-Negative, and Metastatic ER+/HER2- Breast CancersMadeline Gough, Kayden K X Kwah, Tashbib Khan, et al.
Nature Medicine|March 13, 2018
Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signalingPernilla Roswall, Matteo Bocci, Michael Bartoschek, et al.
Pageof 13